News

Company News & Events

ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2016

24 October 2016

BARCELONA, SPAIN and CAMBRIDGE MA.

Oryzon Genomics (Madrid Stock Exchange: ORY) (ISIN Code: ES0167733015), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the third quarter of 2016 and provided an update on the Company's recent developments.

Click here to see the full Press Release

Posted In: 
Investors
News

Share this story